focus -WSS

focus

author：focus 2025-08-23 21:53:36 - browse：2

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Pfizer's Covid pill remains 89% effective in final analysis, company says

WSS

What PEPFAR has meant on the ground in Ukraine

FDA needs staff influx to meet gene therapy needs, Marks says

Pregnancy discrimination could be enabled by AI

Doctor appointment wait times are getting worse

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Make 'food is medicine' a key part of White House nutrition meeting

hotspot

focus

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Meta looks to target Twitter with a rival app called Threads

BioMarin wins approval for gene therapy to treat hemophilia A

Option Care buys Amedisys in $3.6 billion home care deal

Medicare details structure of new drug price negotiation program

Congenital heart disease patients face new threat of heart failure

How one medical school became remarkably diverse

Australia's humpback populations rebound raising hopes of marine scientists

Sports medicine is finally prioritizing gender equality

FDA needs staff influx to meet gene therapy needs, Marks says

knowledge

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Radiology is caught between AI's potential and concern for patients

CMS should re

New case study details death in closely watched Alzhiemer's trial

Pharma patents targeted by Biden in move to slash drug prices

Spinal cord stimulation reduces pain in amputees, study finds

entertainment

hotspot

knowledge

focus